Loading
MET-RADS-P is a standard way to perform and report whole-body MRI in advanced prostate cancer, so that spread to the bones and elsewhere is described the same way from scan to scan.
Whole-body MRI and PET/CT detect metastases in advanced cancers more accurately than CT and bone scans, but whole-body MRI varies in availability and quality. An international panel (Padhani and colleagues, European Urology 2017) wrote the METastasis Reporting and Data System for Prostate Cancer: minimum acquisition protocol, quality standards and interpretation and reporting rules for all forms of advanced prostate cancer. The authors state it needs validation in trials of established and new treatments.
Showing the technology this term belongs to: Whole-body MRI.
Shares PSMA-RADS (PSMA PET reporting system), PCWG3 (Prostate Cancer Clinical Trials Working Group 3), Prostate cancer.
Shares PSMA-RADS (PSMA PET reporting system), PCWG3 (Prostate Cancer Clinical Trials Working Group 3), Prostate cancer.
Shares Whole-body MRI, Prostate cancer.
Shares Whole-body MRI, Prostate cancer.
Shares Whole-body MRI, Prostate cancer.
Shares Whole-body MRI, Prostate cancer.
Shares PSMA-RADS (PSMA PET reporting system), Prostate cancer.
Shares ONCO-RADS (whole-body MRI screening in people at high risk), Whole-body MRI.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/